BEAM
Beam Therapeutics Inc.
There isn't enough reported data to score BEAM yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
BEAM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
BEAM's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
BEAM PE Valuation
BEAM has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
BEAM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect BEAM's losses to grow, with revenue declining. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
BEAM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.84 | +$3.59 |
| Q2 2026 | -$0.66 | +$3.84 |
| Q1 2026 | -$0.48 | +$4.13 |
| Q4 2025 | -$0.81 | +$3.77 |
| Q3 2025 | -$4.43 | -$2.85 |
| Q2 2025 | -$4.50 | -$2.87 |
| Q1 2025 | -$4.61 | -$3.01 |
| Q4 2024 | -$4.58 | -$2.86 |
BEAM is still losing money, but far less than before: $0.84 per share over the past year, against $7.05 at its worst in mid-2021.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over BEAM on earnings quality, reporting a profit while its opponent remains loss making.
BEAM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $307K | -97% |
| Q2 2026 | $490K | -94% |
| Q1 2026 | $31.7M | +325% |
| Q4 2025 | $114.1M | +280% |
| Q3 2025 | $9.7M | -32% |
| Q2 2025 | $8.5M | -28% |
| Q1 2025 | $7.5M | +0.8% |
| Q4 2024 | $30.1M | -90% |
BEAM's revenue is growing: $307,000 last quarter, down 97% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -46033% | -44726 points |
| Q2 2026 | -25827% | -24408 points |
| Q1 2026 | -338% | +1259 points |
| Q4 2025 | -15% | +317 points |
| Q3 2025 | -1308% | -561 points |
| Q2 2025 | -1419% | -528 points |
| Q1 2025 | -1597% | -192 points |
| Q4 2024 | -333% | -375 points |
BEAM's operating margin was −46033% last quarter, down 44726 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over BEAM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over BEAM on profitability, with a higher operating margin.
BEAM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$112M | -$25.5M |
| Q2 2026 | -$68.5M | +$11.1M |
| Q1 2026 | -$130.7M | -$23.8M |
| Q4 2025 | -$87M | -$7.7M |
| Q3 2025 | -$86.5M | +$3.2M |
| Q2 2025 | -$79.6M | +$5.4M |
| Q1 2025 | -$106.9M | -$4.8M |
| Q4 2024 | -$79.3M | -160% |
BEAM has burned cash in almost every quarter: −$398M over the past year, against −$352M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over BEAM on cash generation, producing positive trailing cash flow while its opponent burns cash.
BEAM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +372K shares |
| 1 year | +2.1% | +2.1M shares |
| 3 years | +32% | +25.7M shares |
| 5 years | +58% | +38.3M shares |
| Available history | +241% | +74M shares |
BEAM has 105M diluted shares, up 2.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over BEAM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
BEAM Net Leverage
BEAM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
BEAM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 36.5 | Neutral |
BEAM's weekly RSI is 44 (neutral) and its Stochastic is 37 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
BEAM PE vs Healthcare Sector
BEAM has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BEAM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.0 | 3.7% below |
| 20 week MA | $26.9 | 11% below |
| 50 week MA | $27.8 | 14% below |
| 100 week MA | $25.0 | 3.7% below |
| 200 week MA | $26.7 | 10% below |
BEAM is in a downtrend: it's below all five of its weekly moving averages, and 10% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over BEAM on trend strength, trading above more of its moving averages.
BEAM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.6 | $87.8 | +326% |
| 2021 | $87.8 | $86.5 | -1.5% |
| 2022 | $86.5 | $40.4 | -53% |
| 2023 | $40.4 | $27.2 | -33% |
| 2024 | $27.2 | $26.6 | -2.3% |
| 2025 | $26.6 | $28.0 | +5.2% |
| 2026 YTD | $28.0 | $24.0 | -14% |
BEAM has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.